CMS issues final coverage decision for NGS cancer tests

CMS issued a final National Coverage Determination (NCD) on Friday for next-generation sequencing (NGS) cancer diagnostics, including FoundationOne CDx from Foundation Medicine Inc. (NASDAQ:FMI), that outlines

Read the full 262 word article

User Sign In